About the Ypsomed Group
The Ypsomed Group is the leading developer and manufacturer of injection and infusion systems for self-
medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees.
Ypsomed Diabetes Care
With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9 % p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.
Ypsomed Delivery Systems
Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.
Especially due to the uncertainty surrounding the start of new users on insulin pumps, it is difficult to provide a reliable outlook for the group. In the coming months, we will continue to analyse the situation and evaluate what we can learn from this exceptional situation and what further opportunities it presents for us. For the financial year 2020/21 we expect a growth in turnover and an increase in profitability. From today’s perspective, we still consider our medium-term EBIT target of CHF 100 million to be achievable.
Financial key figures 2019/20
In thousand CHF
|01 April 2019 –
31 March 2020
|in %||01 April 2018 –
31 March 2019
|Sales of goods and services group||393 866||100.0 %||453 765||100.0 %||100 944||352 821|
|Ypsomed Diabetes Care||187 309||47.6 %||280 425||61.8 %||100 944||179 481|
|Ypsomed Delivery Systems||192 032||48.8 %||155 730||34.3 %||155 730|
|Others||14 526||3.7 %||17 610||3.9 %||17 610|
|Operating profit group||9 289||2.4 %||73 344||16.2 %||61 896||11 448|
|Financial income||4 417||1.1 %||3 197||0.7 %|
|Financial expenses||– 6 250||– 1.6 %||– 6 660||– 1.5 %|
|Income taxes||3 996||1.0 %||– 9 744||– 2.1 %|
|Net profit||11 452||2.9 %||60 136||13.3 %|
|Earnings per share in CHF||0.91||4.77|
|Operating profit||9 289||73 344|
|Depreciation and impairment of fixed assets||30 365||25 747|
|Amortisation and impairment of
|22 434||19 141|
|EBITDA (Operating profit before depreciation
|62 088||15.8 %||118 232||26.1 %|